Biohaven Ltd.
Biohaven Ltd. (BHVN): 12 pipeline candidates · 3 upcoming catalysts · ~7 mo cash runway · 15 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
7.2 months
D/E 2.60 · 0% dilution
Lead: Phase 3
12 candidates
3 upcoming, next in ~166d
N/A
A transparent, data-derived signal for Biohaven Ltd.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$2.0B
Cash
$277.1M
Quarterly Burn
$149.9M
Runway
7.2 mo
Revenue
—
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (12 candidates)
| Drug | Phase |
|---|---|
| bhv-1300 | Phase 1 |
| BHV-1400 | Phase 1 |
| bhv-1510 | Phase 1/Phase 2 |
| bhv-1530 | Phase 3 |
| bhv-2100 | Phase 2 |
| bhv-4157 | Phase 1/Phase 2 |
| BHV-7000 | Phase 1 |
| cemiplimab | Phase 1/Phase 2 |
| opakalim | Phase 2/Phase 3 |
| taldefgrobep alfa | Phase 2 |
Showing 10 of 12 candidates. Sign up for full pipeline.
Upcoming Catalysts (3)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
274
Total value held
$1.33B
| Holder | Shares | Value |
|---|---|---|
| janus henderson group plc | 35,069,224 | $296.4M |
| blackrock, inc. | 11,222,407 | $94.9M |
| suvretta capital management, llc | 10,286,937 | $87.0M |
| stifel financial corp | 9,940,885 | $84.1M |
| state street corp | 6,618,803 | $56.0M |
| infinitum asset management, llc | 6,250,000 | $52.9M |
| stempoint capital lp | 3,188,982 | $27.0M |
| royalty pharma sub-manager, llc | 2,936,507 | $24.8M |
| d. e. shaw & co., inc. | 2,847,193 | $24.1M |
| geode capital management, llc | 2,767,763 | $23.4M |
Showing top 10 of 274 institutional holders of Biohaven Ltd.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Biohaven Ltd.'s pipeline?
Biohaven Ltd. (BHVN) has 12 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Biohaven Ltd.'s lead drug candidate?
Biohaven Ltd.'s most advanced tracked candidate is bhv-1300 (Phase 1) for Graves Disease.
What is Biohaven Ltd.'s next catalyst?
Biohaven Ltd.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficac" — expected December 1, 2026.
What is Biohaven Ltd.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Biohaven Ltd. has approximately 7.2 months of cash runway.
What is Biohaven Ltd.'s market capitalization?
Biohaven Ltd.'s market capitalization is approximately $2.0B.
Get the full picture on Biohaven Ltd.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.